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Abstract
Background: This study assessed the Granzyme B (GrB) ELISPOT as a viable alternative to the 51Cr-release assay for
measuring cytotoxic activity of innate immune effector cells. We strategically selected the GrB ELISPOT assay because
GrB is a hallmark effector molecule of cell-mediated destruction of target cells.
Methods: We optimized the GrB ELISPOT assay using the human-derived TALL-104 cytotoxic cell line as effectors
against K562 target cells. Titration studies were performed to assess whether the ELISPOT assay could accurately
enumerate the number of GrB-secreting effector cells. TALL-104 were treated with various secretion inhibitors and
utilized in the GrB ELISPOT to determine if GrB measured in the ELISPOT was due to degranulation of effector cells.
Additionally, CD107a expression on effector cells after effector-target interaction was utilized to further confirm the
mechanism of GrB release by TALL-104 and lymphokine-activated killer (LAK) cells. Direct comparisons between the
GrB ELISPOT, the IFN-γ ELISPOT and the standard 51Cr-release assays were made using human LAK cells.
Results: Titration studies demonstrated a strong correlation between the number of TALL-104 and LAK effector cells
and the number of GrB spots per well. GrB secretion was detectable within 10 min of effector-target contact with
optimal secretion observed at 3–4 h; in contrast, optimal IFN-γ secretion was not observed until 24 h. The protein
secretion inhibitor, brefeldin A, did not inhibit the release of GrB but did abrogate IFN-γ production by TALL-104 cells.
GrB secretion was abrogated by BAPTA-AM (1,2-bis-(2-aminophenoxy)ethane-N,N,N', N'-tetraacetic acid
tetra(acetoxymethyl) ester), which sequesters intracellular Ca2+, thereby preventing degranulation. The number of
effector cells expressing the degranulation associated glycoprotein CD107a increased after interaction with target cells
and correlated with the stimulated release of GrB measured in the ELISPOT assay.
Conclusions: Because of its high sensitivity and ability to estimate cytotoxic effector cell frequency, the GrB ELISPOT
assay is a viable alternative to the 51Cr-release assay to measure MHC non-restricted cytotoxic activity of innate immune
cells. Compared to the IFN-γ ELISPOT assay, the GrB ELISPOT may be a more direct measure of cytotoxic cell activity.
Because GrB is one of the primary effector molecules in natural killer (NK) cell-mediated killing, detection and
enumeration of GrB secreting effector cells can provide valuable insight with regards to innate immunological responses.
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Background
Cytotoxic T-lymphocytes (CTL) and natural killer (NK)
cells play an important role in host defense against intra-
cellular pathogens and tumor cells. CTL recognize target
cells through processed antigenic peptides presented via
MHC. In contrast, NK cells mediate lysis of numerous cel-
lular targets without classical MHC restriction. NK cells
appear to use a variety of different, non-rearranging recep-
tors to initiate cytoxicity and cytokine production [1].
Although CTL and NK differ in the receptors they use to
recognize target cells, they both utilize the granule exocy-
tosis and the Fas ligand (FasL)-mediated pathways to
eliminate altered-self targets [2-6]. The granule-mediated
pathway is the dominant pathway in CTL and NK [5]. CTL
and NK cell granules contain a number of proteins,
including perforin and granzymes, with GrB being the
most abundant granzyme present [7,8]. Upon recognition
and conjunction of the effector cell with the target, pre-
formed granules containing GrB polarize in cytolytic lym-
phocytes at the point of contact and are secreted into the
intercellular space formed between the effector and target
cell [9-14]. The secretion of GrB occurs quite rapidly, is
Ca2+-dependent, and mediates the lethal hit that kills
virus-infected and tumor cells [2,7,8,10,15-19].
Cell-mediated cytotoxicity has conventionally been meas-
ured using the standard 51Cr-release assay [20]. Recently,
the use of the IFN-γ ELISPOT assay as a surrogate measure
for CTL and NK responses has gained increased applica-
tion. However, the IFN-γ ELISPOT assay may not be an
accurate measure of cytotoxic lymphocytes as non-cyto-
toxic cells can secrete IFN-γ. Since GrB is exclusively
present in the granules of CTL and NK cells and is a key
mediator of the granule exocytosis-mediated cytolytic
pathway [21-23], it is an excellent candidate marker for
immunological monitoring of innate immunity by the
ELISPOT method.
The ELISPOT method has been successfully applied to
measure GrB secretion by GrB-transfected CHO cells and
for assessing antigen specific T-cell cytotoxic activity
[24,25]. In this study, we utilized human NK-like and
lymphokine-activated killer (LAK) effector cells to assess
whether the GrB ELISPOT assay could accurately measure
the MHC non-restricted cytolysis that occurs upon recog-
nition of appropriate target cell ligands by activating
receptors on these effector cells. Additionally, we evalu-
ated whether the ELISPOT assay measured GrB release due
to degranulation of stimulated effector cells. The GrB
ELISPOT assay was strategically compared to the IFN-γ
ELISPOT and the standard 51Cr-release assays to deter-
mine if the GrB ELISPOT assay is a viable or better alterna-
tive to measure innate immunity.
Methods
Target cell lines
K562 cells (Human myelogenous leukemia cell line,
ATCC, Manassas, VA) were cultured at 37°C, 5% CO2 in
tissue culture medium (TCM) consisting of RPMI 1640
(BioWhittaker, Walkersville, MD) supplemented with
10% fetal bovine serum (FBS; Hyclone, Logan, UT), 1 mM
non-essential amino acids, 2 mM glutamine, 100 U/ml
Penicillin, 100 µg/ml Streptomycin, 20 mM HEPES and 1
mM sodium pyruvate (Gibco BRL Life Technologies,
Grand Island, NY).
TALL-104 effector cells
The TALL-104 cell line is a T-cell derived line that is highly
cytotoxic for NK-sensitive targets and when grown in the
presence of IL-2, can be stimulated to secrete IFN-γ and
GrB [26,27]. The cell line was cultured in Iscove's modi-
fied Dulbecco's medium (BioWhittaker) supplemented
with 20% FBS (Hyclone), 4 mM glutamine, 100 U/ml
Penicillin and 100 µg/ml Streptomycin (Gibco BRL Life
Technologies) at 8% to 10% CO2. Recombinant human
IL-2 (100 U/ml; Hoffmann-LaRoche, Nutley, NJ) was
added every 2–3 days to ensure optimal growth and main-
tenance of cytotoxic activity.
Generation of human lymphokine-activated killer (LAK) 
cells
Peripheral blood mononuclear cells (PBMC) were iso-
lated from venous blood of normal human volunteers by
buoyant density centrifugation over Ficoll-Paque (Phar-
macia, Piscataway, NJ). Aliquots of effector cells were cry-
opreserved in the vapor phase of liquid N2 for future use
in functional testing. The PBMC were thawed and resus-
pended at 2 × 106 cells/ml in 20 ml of RPMI 1640 (BioW-
hittaker) containing 10% human AB serum (Mediatech,
Herndon, VA), 1 mM non-essential amino acids, 2 mM
glutamine, 1 mM pyruvate, 20 mM HEPES, 100 U/ml
Penicillin and 100 µg/ml Streptomycin (Gibco BRL Life
Technologies). Cell suspensions were stimulated with 100
U/ml of IL-2 (Hoffmann-LaRoche) on day 0 and cultured
for 5 to 6 days at 37°C, 5% CO2. LAK cultures consisted
of 30.0 ± 2.1 % NK cells (CD3-,CD16/CD56+) and 26.9 ±
4.9 CD8+  T-cells as determined by flow cytometric
analysis.
Secretion Inhibitors
TALL-104 cells were treated with inhibitors of cellular
secretion prior to use in the GrB and IFN-γ ELISPOT
assays. Inhibitors used included 1,2-bis-(2-aminophe-
noxy)ethane-N,N,N', N'-tetraacetic acid tetra(acetoxyme-
thyl) ester (BAPTA-AM, Molecular Probes, Eugene, OR), a
cell permeant chelator of intracellular Ca2+, and γ,4-dihy-
droxy-2-[6-hydroxy-1-hep-tenyl]-4-cyclopentanecrotonic
acid λ-lactone (brefeldin A; Sigma, St. Louis, MO) which
blocks protein secretion. TALL-104 cells were resuspendedJournal of Translational Medicine 2004, 2:31 http://www.translational-medicine.com/content/2/1/31
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at 2.5 × 105 cells/ml and 2.5 × 104 cells/ml in PBS without
divalent cations for BAPTA-AM and brefeldin A treatment,
respectively. Cells were pretreated with the indicated con-
centrations of BAPTA-AM for 45 min or with 5 µg/ml
brefeldin A for 1 h at 37°C, washed twice, assessed for via-
bility by trypan blue exclusion, and resuspended at 2.5 ×
104 cells/ml in assay media.
51Cr-release assay
Cytotoxicity of TALL-104 and LAK cells was assessed using
the standard 51Cr-release assay. Briefly, one million target
cells were labeled at 37°C for 1 h with 100 µCi Na2
51CrO4
(New England Nuclear, Boston, MA). Target cells were
washed and resuspended in TCM at 5 × 104 cells/ml. Five
thousand target cells per well (100 µl) were added to a 96
well plate (Costar, Cambridge, MA) following the appro-
priate number of effector cells (100 µl/well). The defined
effector:target (E:T) ratios were plated in triplicate. Cyto-
toxicity assays were performed at 37°C for 4 h. Percent
specific lysis was calculated using the following equation:
(ER - SR)/(MR - SR) × 100,
where ER = experimental release, SR = spontaneous
release and MR = maximum release.
Granzyme B ELISPOT assay
Granzyme B secretion was measured using the GrB ELIS-
POT assay as previously described [25]. Briefly, Multi-
Screen-IP plates (PVDF membrane, Millipore, Bedford,
MA) were coated overnight at 4°C with 100 µl/well of
anti-human GrB antibody (7.5 µg/ml in PBS, clone GB-
10, PeliCluster, Cell Sciences, Norwood MA). Effector
cells (100 µl/well) were added to triplicate wells at speci-
fied concentrations followed by 5 × 104 target cells per
well (100 µl). After the specified effector-target cell incu-
bation, the plates were washed and 100 µl/well of bioti-
nylated anti-human GrB detecting antibody (0.25 µg/ml
in PBS/1% BSA/0.05% Tween 20, clone GB-11, PeliClus-
ter, Cell Sciences) was added. Plates were incubated for 3
h and 50 µl of Streptavidin-Alkaline Phosphatase (1:1500
in PBS/1% BSA, Gibco BRL Life Technologies) was added
for 1 h. Spots were visualized with 100 µl/well of BCIP-
NBT phosphatase substrate (KPL, Gaithersburg, MD) and
subjected to automated evaluation using the ImmunoS-
pot Imaging Analyzer system (Cellular Technology Ltd,
Cleveland, OH).
IFN-γ ELISPOT assay
For assessing IFN-γ secretion, MultiScreen-IP plates (PVDF
membranes, Millipore) were coated overnight at room
temperature with 50 µl/well of anti-human IFN-γ anti-
body (20 µg/ml in PBS, Biosource, International,
Camarillo CA) as previously described [25]. After effector
and target cells were incubated at 37°C, the plates were
washed and 50 µl/well of biotinylated anti-human IFN-γ
antibody (1.3 µg/ml in PBS/1% BSA/0.05% Tween 20, BD
PharMingen, San Jose, CA) was added. Plates were incu-
bated with biotinylated antibody, washed and 50 µl of
Streptavidin-Alkaline Phosphatase (1:1500 in PBS/1%
BSA, Gibco BRL Life Technologies) was added. Spots were
visualized and enumerated as described above.
CD107a mobilization assay
Degranulation of TALL-104 and LAK cells in response to
target cell recognition was assessed by monitoring surface
antigen expression of CD107a (lysosomal-associated
membrane protein-1), a surface antigen transiently
present on the cell surface after release of cytolytic gran-
ules. Expression of CD107a has been used as a marker to
measure degranulation by flow cytometry [28,29].
To distinguish target cells from effector cells, K562 cells
were first labeled with PKH67 dye (Sigma) according to
the manufacturer's instructions and washed extensively
prior to use in the assay. Effector cells (2 × 105) were resus-
pended in 400 µl of phenol red-free TCM in polystyrene
tubes (Falcon, Franklin Lakes, NJ). PKH67-labeled K562
target cells (1 × 105 cells in 50 µl) were then added to
appropriate tubes, the tubes were spun for 30 sec at 500
rpm and incubated for the specified periods in a 37°C
water bath. Reactions were quenched with cold PBS and
then 20 µl of CD107a-PE-Cy5 (PharMingen) was added.
Mouse IgG1-biotin (Beckman-Coulter, Miami, FL) and
streptavidin-PE-Cy5 (Caltag, Burlingame, CA) were uti-
lized for controls. Tubes were incubated with antibody for
20 min at room temperature, washed with buffer and ana-
lyzed using a FACScan instrument (Becton-Dickinson
Immunocytometry Systems, San Jose, CA) equipped with
a 15 mW argon-ion laser. The percent of effector cells
expressing CD107a was determined by gating the PKH67
negative (effector cells) population. Within the PKH67
negative gate, CD107a expression was determined from
histograms based on forward and side scatter analysis.
Effector cells run in the absence of target cells were evalu-
ated for baseline expression of CD107a. The percentage of
effector cells induced by target cells to express CD107a
was calculated by subtracting background (spontaneous)
expression from experimental samples.
Statistical analysis
Statistical analysis was performed using Student's t test
and Pearson correlation coefficient (R2).
Results
GrB release by stimulated TALL-104 cells
GrB ELISPOT assays were performed using a constant
number of K562 targets and decreasing numbers of TALL-
104 effector cells per well. As the number of TALL-104
cells decreased, the resulting number of GrB spotsJournal of Translational Medicine 2004, 2:31 http://www.translational-medicine.com/content/2/1/31
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decreased linearly. Limited GrB spots were detected in
wells containing TALL-104 alone demonstrating that the
ELISPOT assay measured primarily stimulated release of
GrB (Fig. 1). K562 alone did not secrete GrB (data not
shown). The correlation between the number of spots per
well and the number of TALL-104 was highly significant
with a Pearson correlation coefficient of R2 = 0.98. There-
fore, the GrB ELISPOT assay is capable of measuring the
frequency of effector cells stimulated to secrete GrB.
Correlation of GrB secretion and cytotoxic activity
In tandem with the GrB ELISPOT assay, TALL-104 cells
were also utilized as effectors against K562 targets in the
standard 51Cr-release assay to assess lytic activity. Signifi-
cant specific lysis was observed at effector:target ratios
from 10:1 to 1:1 (Table 1). In contrast to the ELISPOT
assay, that can measure the frequency of cytotoxic cells at
effector:target ratios as low as 0.02:1, specific lysis was not
significant in the 51Cr-release assay at cell ratios below 1:1
(Table 1). However, when optimal ratios were used in
each individual assay, similar trends between the number
of GrB spots per well in the ELISPOT and specific lysis in
the 51Cr-release assay were observed. These data demon-
strate that the release of GrB is indicative of cytolytic
activity.
Granzyme B release by stimulated TALL-104 cells measured in the ELISPOT assay Figure 1
Granzyme B release by stimulated TALL-104 cells measured in the ELISPOT assay. TALL-104 cells (1 × 103, 2 × 
103 or 5 × 103 cells per well) were incubated with K562 targets (5 × 104 cells per well) for 4 h at 37°C in the Granzyme B ELIS-
POT assay (effector:target cell ratios are in brackets). Data are presented as average number of spots per well ± SD and are 
representative of 3 experiments with similar results. A significant correlation between the number of spots per well and effec-
tor cell number was observed (R2 = 0.98).
TALL-104 only TALL-104 + K562
5 K
(0.1:1)
1 K
(0.02:1)
2 K
(0.04:1)
26 ± 6
6 ± 2
69 ± 4 13 ± 3
129  ± 22
33 ± 7Journal of Translational Medicine 2004, 2:31 http://www.translational-medicine.com/content/2/1/31
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Secretion kinetics of GrB and IFN-γ
To measure the secretion kinetics of GrB compared to IFN-
γ, TALL-104 cells were incubated with K562 target cells for
the indicated times in the ELISPOT assays. Secretion of
GrB was compared to IFN-γ because IFN-γ is currently the
standard utilized to measure the frequency of cytotoxic
cells via the ELISPOT method. GrB secretion was observed
within 10 min of effector-target cell interaction with opti-
mal secretion around 3–4 h (Fig. 2). This observation is in
contrast to maximum IFN-γ production, which was
observed at 24 h of effector-target interaction (data not
shown). These data are consistent with rapid effector cell
degranulation (within minutes) upon contact with target
cells [18,19].
Mechanism of GrB secretion
Effects of secretion inhibitors on the release of GrB and
IFN-γ in the ELISPOT assays as well as expression of
CD107a on effector cells were evaluated to determine the
possible mechanism of GrB release measured in the ELIS-
POT assay. TALL-104 cells were treated with inhibitors of
cellular secretion and assessed for their ability to release
GrB and IFN-γ in the ELISPOT assays. BAPTA-AM chelates
intracellular Ca2+ and was utilized to block degranulation.
Brefeldin A, which blocks protein secretion, was utilized
to prevent secretion of newly synthesized proteins.
Loading TALL-104 cells with BAPTA-AM resulted in a
dose-dependent inhibition of GrB secretion (Fig. 3). Inhi-
bition of GrB was not attributed to alterations in cell via-
bility as TALL-104 cells loaded with as high as 100 µM of
BAPTA-AM remained viable as assessed by trypan blue
exclusion (data not shown). Brefeldin A treatment did not
alter the secretion of GrB when TALL-104 cells were stim-
ulated with K562 targets but did significantly (p < 0.05)
inhibit IFN-γ secretion (Fig. 4). Additionally, increased
expression of the degranulation marker, CD107a, on
TALL-104 cells was observed when TALL-104 cells were
incubated with K562 target cells. Compared to TALL-104
cells alone, the addition of K562 targets induced 13.75%
of TALL-104 cells to express CD107a (Fig. 5). Taken
together, these data are consistent with synthesis of IFN-γ
de novo while GrB is released from preformed granules
upon effector-target interaction.
Application of the GrB ELISPOT assay to assess innate 
immunity
To address the potential clinical relevance of the GrB ELIS-
POT assay, LAK cells derived from PBMC, rather than the
TALL-104 cell line, were utilized as effector cells. As
shown in Figure 6, the number of GrB spots per well cor-
related with the number of LAK cells added, results com-
parable to those obtained with TALL-104 cells. Only wells
containing both LAK and K562 target cells contained a
substantial number of spots (Fig. 6).
The secretion kinetics of GrB and IFN-γ by LAK cells were
similar to that observed for TALL-104 cells. GrB secretion
was seen within 10 min of effector-target cell interaction
with optimal secretion around 3 h and maximal IFN-γ
production was observed at 24 h of effector-target interac-
tion (Fig. 7). Similarly, stimulated secretion of GrB by LAK
cells was associated with increased surface expression of
the degranulation marker, CD107a. The correlation
between the number of GrB spots and the number of cells
expressing CD107a per 100,000 effector cells was signifi-
cant (R2 = 0.89, Fig. 8). These data demonstrate that the
GrB ELISPOT assay accurately measures the rapid release
of GrB by stimulated LAK cells and can enumerate GrB-
secreting effector cells.
Table 1: Comparison of the GrB ELISPOT and 51Cr-release assays for measuring TALL-104 cell activity.
Effector:Target Ratio 51Cr-Release Assaya (% Cytotoxicity ± SE) GrB ELISPOT Assayb (Spots/well ± SE)
10:1 65 ± 4 TNTCc
5:1 57 ± 10 TNTC
2.5:1 47 ± 11 TNTC
1:1 20 ± 5 TNTC
0.5:1 9 ± 2 TNTC
0.2:1 2 ± 1 316 ± 50
0.1:1 2 ± 1 144 ± 13
0.05:1 1 ± 1 80 ± 6
0.02:1 0 ± 1 33 ± 4
a The 51Cr-release assay was performed with the effector:target cell ratio as specified for 4 h at 37°C. Data presented as average cytotoxicity ± SE 
(n = 3).
bThe granzyme B ELISPOT assay was performed with K562 cells at a constant number of 5 × 104 cells per well and effector:target cell ratio as 
specified for 4 h at 37°C. Data presented as average spots/well ± SE (n = 3).
cTNTC= Too numerous to count accurately.Journal of Translational Medicine 2004, 2:31 http://www.translational-medicine.com/content/2/1/31
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LAK cells were utilized in the GrB ELISPOT, IFN-γ ELIS-
POT and 51Cr-release assays to evaluate the different
assays for measuring innate immunity (Table 2). Both
ELISPOT assays were significantly more sensitive than the
51Cr-release assay. At effector:target ratios of 20:1-5:1, sig-
nificant specific lysis can be measured by the 51Cr-release
Kinetics of Granzyme B and IFN-γ secretion by TALL-104  cells in the ELISPOT assays Figure 2
Kinetics of Granzyme B and IFN-γ secretion by 
TALL-104 cells in the ELISPOT assays. TALL-104 cells 
(2.5 × 103 cells per well) were incubated with K562 cells (5 × 
104 cells per well) in the Granzyme B and IFN-γ ELISPOT 
assays for 0.2, 0.5, 1, or 4 h at 37°C. Data are presented as 
average spots per well ± SD. Results are corrected for back-
ground and are representative of 3 experiments with similar 
results.
Effect of BAPTA-AM on Granzyme B secretion by TALL-104  cells Figure 3
Effect of BAPTA-AM on Granzyme B secretion by 
TALL-104 cells. TALL-104 cells were pretreated with the 
indicated concentrations of BAPTA-AM for 45 min at 37°C. 
TALL-104 cells (2.5 × 103 cells per well) were incubated with 
K562 (5.0 × 104 cells per well) for 4 h in the Granzyme B 
ELISPOT assay. Data are presented as spots per well ± SE (n 
= 3). Results are corrected for background.
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Effect of Brefeldin A on Granzyme B and IFN-γ secretion in  the ELISPOT assays Figure 4
Effect of Brefeldin A on Granzyme B and IFN-γ secre-
tion in the ELISPOT assays. TALL-104 cells were prein-
cubated with brefeldin A (5 µg/ml; 1 h at 37°C) prior to use 
in the ELISPOT assays. TALL-104 cells (2.5 × 103 cells per 
well) were incubated with K562 (5 × 104 cells per well) for 4 
h in the Granzyme B and 24 h in the IFN-γ ELISPOT assays at 
37°C. Data are presented as percent inhibition ± SE (n = 3). 
Results are corrected for background.
Stimulated TALL-104 cells express the degranulation marker  CD107a Figure 5
Stimulated TALL-104 cells express the degranulation 
marker CD107a. TALL-104 (2 × 105 cells) were incubated 
with K562 (1 × 105 cells) and surface expression of CD107a 
was determined by flow cytometric analysis. K562 were 
prelabeled with PKH67 dye to differentiate effector cells 
from targets. The histograms represent the PE-Cy5 CD107a 
positive cells determined by forward versus side scatter of 
the gated effector cells. TALL-104 cells alone are repre-
sented by the open histogram and TALL-104 cells incubated 
with K562 for 1 h are represented by the shaded histogram. 
The data is representative of 3 experiments with similar 
results.
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assay but the spots per well in the ELISPOT assays were
too numerous to count accurately. Significant IFN-γ and
GrB secretion was evident at effector:target ratios as low as
0.02:1 (1000 effectors/well) therefore, the optimal ratios
for the ELISPOT assays are below the level of sensitivity of
the 51Cr-release assay (Table 2). However, when the opti-
mal number of LAK cells are used in each individual assay,
the amount of GrB and IFN-γ secreting cells in the ELIS-
POT assays and cytotoxicity in the 51Cr-release assay have
shown cross-correlation with R2 values greater than 0.86
for all combinations. When comparing the two ELISPOT
assays, the GrB ELISPOT is more rapid and may be a more
direct measure of cytotoxic activity than the IFN-γ ELIS-
POT. Therefore, the GrB ELISPOT assay can elucidate the
frequency of GrB secreting cells in primary LAK cultures
and can be applied to measure innate immunity in clini-
cally relevant samples.
Discussion
NK cells are a key part of innate immunity due to their
ability to secrete cytokines and mediate cytolytic activity
and act as an important first line of defense against virally
infected cells and tumor cells [30]. Although cytokine
secretion by NK cells plays a role in regulating the adap-
tive immune response, cell-mediated cytotoxicity is the
major effector function of NK cells. NK cells can mediate
Granzyme B release by stimulated LAK cells measured in the ELISPOT assay Figure 6
Granzyme B release by stimulated LAK cells measured in the ELISPOT assay. Human peripheral blood mononu-
clear cells (PBMC) were cultured with 100 U/ml of IL-2 for 5–6 days to induce LAK cells. LAK cells (1 × 103, 3 × 103 or 1 × 104 
cells per well) were incubated with K562 (5 × 104 cells per well) for 4 h at 37°C. Effector:target cell ratios are in brackets. Data 
are presented as average number of spots per well ± SD and are representative of 5 experiments with similar results. A signif-
icant correlation between the number of spots per well and effector cell number was observed (R2 = 0.94).
10K
(0.2:1)
3K
(0.06:1)
1K
(0.02:1)
LAK + K562
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74 ± 7
LAK only
1± 1
3 ± 2
16 ± 9Journal of Translational Medicine 2004, 2:31 http://www.translational-medicine.com/content/2/1/31
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cytotoxicity by two main pathways, FasL-mediated and
granule-mediated. The granule-mediated pathway,
however, is dominant in NK cells with the release of GrB
as one of the key factors in the lethal interaction that kills
virus-infected and tumor cells [2,5,7,8,10,15-19]. There-
fore, evaluating the secretion of this molecule provides an
indirect measure of cell-mediated cytotoxicity mediated
via the release of granules.
The GrB ELISPOT assay has been previously applied to
enumerate the frequency of antigen-specific T cells and
this release of GrB by T cells was indicative of cytolytic
ability [24,25,31]. Moreover, the GrB ELISPOT assay
requires significantly less effector cells than the standard
51Cr-release assay [24,25]. In this study, we demonstrated
that the GrB ELISPOT assay can be utilized to determine
the frequency and potential cytolytic ability of innate
immune cells. When TALL-104 or LAK cells were used as
effectors, our results were in excellent agreement with
results obtained when GrB-transfected CHO cells, T-cell
lines or CTL stimulated in vitro, were employed as effector
cells [24,25]. TALL-104 or LAK cells secreted significant
amounts of GrB only when stimulated with an NK-sensi-
tive target cell line indicating that the GrB ELISPOT assay
primarily detected stimulated, and not spontaneous (con-
stitutive), release of GrB. Although assessing GrB release is
an indirect measure of target cell lysis, a similar trend
between the number of GrB spots per well in the ELISPOT
assay and specific lysis in the 51Cr-release was observed.
Therefore, the GrB ELISPOT assay is a viable alternative to
the 51Cr-release assay for measuring MHC non-restricted
cytolytic activity.
Preformed granules that contain mature GrB are constitu-
tively expressed in NK cells, thus NK cells are always
armed with functional GrB. Preformed GrB is rapidly
released upon recognition and conjunction of the effector
cell and this process is Ca2+-dependent [18,19,32]. In con-
trast, IFN-γ is produced de novo upon activation and is
secreted within hours [33]. The differences observed in
the pattern of GrB and IFN-γ secretion suggest that the GrB
measured in the ELISPOT assay is due to degranulation of
pre-formed GrB whereas IFN-γ secretion results from pro-
tein synthesis de novo.
To confirm that GrB measured in the ELISPOT assay was
released via degranulation, effector cells were treated with
inhibitors of cellular secretion: brefeldin A, BAPTA-AM
Kinetics of Granzyme B and IFN-γ secretion by LAK cells in  the ELISPOT assays Figure 7
Kinetics of Granzyme B and IFN-γ secretion by LAK 
cells in the ELISPOT assays. Human peripheral blood 
mononuclear cells (PBMC) were cultured with 100 U/ml of 
IL-2 for 5–6 days to induce LAK cells. LAK cells (5 × 103 cells 
per well) were incubated with K562 cells (5 × 104 cells per 
well) in the Granzyme B and IFN-γ ELISPOT assays for 0.2, 
0.5, 1, 4 or 24 h at 37°C. Data are presented as average 
spots per well ± SE (n = 6). Results are corrected for 
background.
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Correlation between CD107a expression measured in the  flow cytometric assay and Granzyme B release measured in  the ELISPOT assay Figure 8
Correlation between CD107a expression measured 
in the flow cytometric assay and Granzyme B release 
measured in the ELISPOT assay. Human peripheral 
blood mononuclear cells (PBMC) were cultured with 100 U/
ml of IL-2 for 5–6 days to induce LAK cells. LAK cells (5 × 
103 cells per well) were incubated with K562 cells (5 × 104 
cells per well) in the Granzyme B ELISPOT and 2 × 105 LAK 
cells were incubated with 1 × 105 K562 in the CD107a mobi-
lization assay for 0.5, 1 and 3 h. The ELISPOT data are pre-
sented as spots per 1.0 × 105 effectors ± SE (n = 9) and the 
CD107a data as the number of positive cells per 1.0 × 105 
effectors ± SE (n = 9). All results are corrected for back-
ground. A significant correlation between the number of GrB 
spots and CD107a positive effector cells was observed (R2 = 
0.89).
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and EGTA. Brefeldin A reversibly disrupts protein
translocation from the endoplasmic reticulum to the
Golgi apparatus, blocking the production and subsequent
secretion of newly synthesized proteins [34]. BAPTA-AM
and EGTA are both Ca2+-chelating agents and therefore
can block Ca2+-dependent degranulation. Cell permeant
BAPTA-AM contains acetoxymethyl ester groups that are
removed by cytosolic nonspecific esterases, trapping the
chelator within the cell. In a series of experiments, treat-
ment of effector cells with brefeldin A significantly
decreased IFN-γ, but not GrB secretion, whereas, BAPTA-
AM abrogated GrB secretion but its effect on IFN-γ secre-
tion was not apparent (data not shown). EGTA, which
sequesters extracellular Ca2+, could also abrogate GrB
secretion measured in the ELISPOT assay. However, sig-
nificantly higher concentrations of EGTA (4–40 mM)
than BAPTA-AM were needed to block GrB secretion (data
not shown). These data are in good agreement with
recently published findings [35] which demonstrate that
higher concentrations of EGTA are needed to block
degranulation compared to BAPTA-AM. Although adher-
ence of cytolytic cells to their targets is a prerequisite for
granule release, this interaction is dependent on Mg2+, but
not Ca2+ [19]. Thus, the decrease in GrB secretion after
BAPTA-AM and EGTA treatment cannot be attributed to
inhibition of adhesion between the effector and target
cells, but results from inhibition of degranulation.
Recently, a flow cytometric assay based on CD107a (lyso-
somal-associated membrane protein-1) mobilization was
developed to measure degranulation of cytolytic cells
[28,29]. CD107a is a vesicle membrane protein of cyto-
lytic granules that is transiently expressed on the surface of
effector cells during degranulation. Correlations between
direct lytic ability and surface expression of CD107a on
effector cells has been shown, indicating that CD107a
expression is a reliable measure of cytolytic capacity
[28,29]. In our study, CD107a expression correlated with
GrB secretion (R2 = 0.89). Both the release of GrB and the
expression of CD107a was observed as early as 30 min
after LAK cells were stimulated with relevant target cells,
and increased with extended effector-target cell interac-
tion. These data confirm that the GrB ELISPOT assay is an
excellent measure of cytotoxic capacity mediated by effec-
tor cell degranulation.
When the ELISPOT assays were directly compared to the
51Cr-release assay, they demonstrated higher sensitivity
with both TALL-104 and LAK cells as effector cells, data
consistent with previous studies [24,25,36,37]. The ELIS-
POT assays enumerate antigen specific lymphocyte fre-
quency by measuring secretion of specific immune
proteins engaged in the specific pathway utilized to medi-
ate lysis of target cells, whereas the 51Cr-release assay
measures cytotoxic ability regardless of the mechanisms
of the killing. Therefore, unlike the 51Cr-release assay, the
ELISPOT assays are both qualitative and quantitative.
It is important to emphasize that 51Cr-release and the GrB
ELISPOT assay measure different aspects of cell-mediated
killing – target cell death and effector cell function, respec-
tively. A limitation of the GrB ELISPOT assay is that it
measures degranulation, not direct target cell lysis. As
such, degranulation may not always equate to cell death if
Table 2: Comparison of the GrB ELISPOT, IFN-γ ELISPOT and 51Cr-release assays for measuring Lymphokine Activated Killer (LAK) 
cell activity.
Effector:Target Ratio 51Cr-Release Assaya
(% Cytotoxicity ± SE)
IFN-γ ELISPOT Assayb
(Spots/well ± SE)
GrB ELISPOT Assayc
(Spots/well ± SE)
20:1 42 ± 10 TNTCd TNTC
10:1 30 ± 10 TNTC TNTC
5:1 22 ± 6 TNTC TNTC
2.5:1 10 ± 3 TNTC TNTC
1:1 5 ± 1 TNTC TNTC
0.4:1 4 ± 1 227 ± 16 282 ± 18
0.2:1 2 ± 1 182 ± 8 193 ± 12
0.1:1 2 ± 2 121 ± 14 117 ± 12
0.04:1 1 ± 0 61 ± 13 54 ± 11
0.02:1 1 ± 0 29 ± 8 37± 7
a The 51Cr-release assay was performed with the effector:target cell ratio as specified for 4 h at 37°C. Data presented as average cytotoxicity ± SE 
(n = 3).
b The IFN-γ ELISPOT assay was performed with K562 cells at a constant number of 5 × 104 cells per well and effector:target cell ratio as specified 
for 24 h at 37°C. Data presented as average spots/well ± SE (n = 3).
cThe granzyme B ELISPOT assay was performed with K562 cells at a constant number of 5 × 104 cells per well and effector:target cell ratio as 
specified for 4 h at 37°C. Data presented as average spots/well ± SE (n = 3).
dTNTC= Too numerous to count accurately.Journal of Translational Medicine 2004, 2:31 http://www.translational-medicine.com/content/2/1/31
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target cells contain serpin proteinase inhibitor 9 (PI9), a
protein that inhibits the proteolytic activity of GrB, [38] or
if effector cells are perforin deficient. The GrB ELISPOT
assay also does not account for cytotoxicity mediated by
FasL pathway. Therefore, when appropriate, the two
assays should be used in concert. However, the high sen-
sitivity and specificity of the ELISPOT assay are beneficial
for monitoring clinical trials where frequently there are
limited numbers of patients' cells available or target cells
cannot be effectively labeled. Target cells that resist or do
not tolerate labeling, such as some primary tumor cells,
can still be utilized in the GrB ELISPOT assay. Addition-
ally, compared to the 51Cr-release assay, the GrB ELISPOT
provides the precusory frequency of cells with the poten-
tial to kill targets. Although a number of flow cytometric
assays have been developed to assess target cell cytotoxic-
ity as well as identify the phenotype of the effector cells
mediating the immune response, these assays are not as
sensitive as the ELISPOT assay.
The use of the IFN-γ ELISPOT assay as a surrogate measure
for CTL and NK responses has recently gained increased
application as an alternative to the 51Cr-release assay
[36,39-43]. However, the IFN-γ ELISPOT assay may not be
an accurate measure of cytotoxic lymphocytes since 1)
non-cytotoxic cells can secrete IFN-γ and 2) CTL with lytic
activity do not always secrete IFN-γ [44-48]. The release of
GrB is a more specific measure of cytotoxic lymphocytes
than IFN-γ because the expression of GrB is restricted to
CTL and NK cells [8,49,50]. Therefore, the GrB ELISPOT
assay may be a more direct measure of innate immunity
compared to the IFN-γ ELISPOT. The high sensitivity and
specificity of the ELISPOT assays are beneficial for moni-
toring clinical trials where frequently there are limited
numbers of patients' cells available. As such,
simultaneous use of the IFN-γ and GrB ELISPOT assays
may provide important immunological insight into
patient responses that may then be directly assessed
against clinical outcome.
Conclusion
Our data demonstrate that the GrB ELISPOT assay is a via-
ble alternative to the standard 51Cr-release assay to meas-
ure granule-mediated cytotoxicity and could be easily
adapted to reliably and accurately measure MHC non-
restricted cytotoxicity indicative of NK and LAK activity.
The GrB ELISPOT assay measured GrB release due to
degranulation of stimulated effector cells. Additionally,
GrB is a more specific candidate marker than IFN-γ to
measure the cytotoxic capacity of innate immune effector
cells such as NK cells.
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